X
AKBA icon

Xponance’s Akebia Therapeutics AKBA Stock Holding History

Xponance’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.7K Buy
22,782
+2,837
+14% +$3.9K ﹤0.01% 1655
2025
Q4 		$32.1K Buy
19,945
+399
+2% +$835 ﹤0.01% 1550
2025
Q3 		$53.4K Buy
19,546
+217
+1% +$722 ﹤0.01% 1485
2025
Q2 		$70.4K Buy
19,329
+3,529
+22% +$9.7K ﹤0.01% 1440
2025
Q1 		$30.3K Buy
15,800
+1,511
+11% +$3.08K ﹤0.01% 1414
2024
Q4 		$27.1K Buy
14,289
+588
+4% +$1.02K ﹤0.01% 1430
2024
Q3 		$18.1K Hold
13,701
– – ﹤0.01% 1382
2024
Q2 		$14K Buy
+13,701
New +$16.9K ﹤0.01% 1314

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Xponance's AKBA Position: Q1 2026 in Review

Xponance increased its Akebia Therapeutics (AKBA) stake by 14% in Q1 2026, buying an estimated $3.9K and bringing the position to 22,782 shares worth $31.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Xponance first reported a position in AKBA in Q2 2024 and has held it in 8 quarters since. The position peaked at $70.4K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Xponance held 22,782 shares of Akebia Therapeutics worth $31.7K as of Q1 2026.
  • Xponance bought 2,837 Akebia Therapeutics shares in Q1 2026, an estimated $3.9K.
  • Akebia Therapeutics made up ﹤0.01% of Xponance's portfolio in Q1 2026, its #1655 holding.
  • Xponance first reported a position in Akebia Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Xponance's Akebia Therapeutics position peaked at $70.4K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Xponance's 13F filing for Q1 2026, filed 13 May 2026.